Skip to main content
Premium Trial:

Request an Annual Quote

FDA Issues Emergency Use Authorization for GenMark Coronavirus Assay

NEW YORK – The US Food and Drug Administration has issued Emergency Use Authorization for GenMark Diagnostics' ePlex SARS-CoV-2 Test, the firm announced Thursday evening.

The test qualitatively detects SARS-CoV-2 virus in nasopharyngeal swab samples and is for use on GenMark's sample-to-answer ePlex system, which is based on competitive DNA hybridization and electrochemical detection technology.

The company noted that the global installed base of the instrument stood at more than 500 as of the end of 2019 and added that the platform provides results in less than two hours and can process up to 96 tests per eight-hour shift.

During GenMark's fourth quarter earnings conference call earlier this month, it said that it had begun shipping its SARS-CoV-2 tests to its distributor in Hong Kong and to hospitals in the US, and that it would use information from customers using the test, which was then research use only, to apply to the FDA for EUA.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.